Anemia of chronic kidney disease: A combined effect of marginal iron stores and erythropoietin deficiency

Dialysis and Transplantation

Volumn 33, Issue 12, 2004, Pages

  Schwartz, Allan B ^a   Prasad, Vinod ^a   Garcha, Jasjot ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; FERROUS FUMARATE; FERROUS GLUCONATE; FERROUS SULFATE; HEMOGLOBIN; HISTAMINE H2 RECEPTOR ANTAGONIST; IRON; IRON DEXTRAN; RECOMBINANT ERYTHROPOIETIN; TETRACYCLINE DERIVATIVE;

ABDOMINAL PAIN; ANEMIA; BONE MARROW; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CONSTIPATION; DIALYSIS; DIARRHEA; EPIGASTRIC PAIN; ERYTHROPOIESIS; GASTROINTESTINAL TOXICITY; HEARTBURN; HUMAN; HYPOTENSION; INFECTION; IRON DEFICIENCY ANEMIA; IRON STORAGE; KIDNEY FUNCTION; MEAN CORPUSCULAR VOLUME; MORBIDITY; MORTALITY; NAUSEA; PRIORITY JOURNAL; REVIEW; URTICARIA; VOMITING;

EID: 19744381031     PISSN: 00902934     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Besarab A, Ross RP, Nasca TJ. The use of recombinant human erythropoietin in predialysis patients. Curr Opin Nephrol Hypertens 1995; 4(2):155-161.
2. Schwartz AB, Orquiza CS. The effects of recombinant human erythropoietin on mean corpuscular volume in patients with the anemia of chronic renal failure. Clin Nephrol 1995; 43(4):256-259.
3. Van Wych DB. Iron management during recombinant human erythropoietin therapy. Am J Kid Dis 1989; 14:9-13.
4. Beutler E, Fairbanks VF, Fahey JL. The metabolism of iron. In: Clinical Disorders of Iron Metabolism. New York: Grune & Stratton Inc., 1963, pp 19-64.
5. Haen PJ. Iron deficiency anemia. In: Young LH (ed.), Principles of Hematology. Dubuque, IA: William C. Brown Publishers, 1995, pp 118-125.
6. Huebers HA, Huebers E, Csiba E, et al. The significance of transferrin for intestinal iron absorption. Blood 1983; 61:283-290.
7. Banerjee D, Flanagan PR, Cluett J, Valberg LS. Transferrin receptors in the human gastrointestinal tract: relationship to body iron stores. Gastroenterology 1986; 91(4):861-869. PMID: 3017805 [PubMed - indexed for MEDLINE].
8. Linder MC, Munro HN. The mechanism of iron absorption and its regulation. Fed Proc 1977; 36(7):2017-2023.
9. Morris ER. An overview of current information on bioavailability of dietary iron to humans. Fed Proc 1983; 42:1716-1720.
10. Gillooly M, et al. The effects of organic acids, phytates and polyphenols on the absorption of iron from vegetables. Br J Nutr 1983; 49:331-342.
11. Moore CV. The importance of nutritional factors in the pathogenesis of iron-deficiency anemia. Am J Clin Nutr 1955; 3:3; Scand J Clin Lab Invest 1957; 9:292; Harvey Lect Series 1961; 55:67; International Symposium on Iron Metabolism. Berlin: Springer, 1964; series Haemotol 1965; 6:1.
12. Moore CV. The importance of nutritional factors in the pathogenesis of iron-deficiency anemia. Am J Clin Nutr 1955; 3:3; Scand J Clin Lab Invest 1957; 9:292; Harvey Lect Series 1961; 55:67; International Symposium on Iron Metabolism. Berlin: Springer, 1964; series Haemotol 1965; 6:1.
13. Moore CV. The importance of nutritional factors in the pathogenesis of iron-deficiency anemia. Am J Clin Nutr 1955; 3:3; Scand J Clin Lab Invest 1957; 9:292; Harvey Lect Series 1961; 55:67; International Symposium on Iron Metabolism. Berlin: Springer, 1964; series Haemotol 1965; 6:1.
14. Moore CV. The importance of nutritional factors in the pathogenesis of iron-deficiency anemia. Am J Clin Nutr 1955; 3:3; Scand J Clin Lab Invest 1957; 9:292; Harvey Lect Series 1961; 55:67; International Symposium on Iron Metabolism. Berlin: Springer, 1964; series Haemotol 1965; 6:1.
15. Moore CV. The importance of nutritional factors in the pathogenesis of iron-deficiency anemia. Am J Clin Nutr 1955; 3:3; Scand J Clin Lab Invest 1957; 9:292; Harvey Lect Series 1961; 55:67; International Symposium on Iron Metabolism. Berlin: Springer, 1964; series Haemotol 1965; 6:1.
16. Cook JD, Dassenko SA, Whittaker P. Calcium supplementation: effect on iron absorption. Am J Clin Nutr 1991; 53:106-111.
17. Cavill I, Ricketts C. The kinetics of iron metabolism. In: Jacobs A, Worwood M (eds.), Iron Chemistry and Medicine. New York: Academic Press 1975.
18. Dormandy TL. Biological rancidification. Lancet 1969; 2(7622):684-688.
19. Hallberg L, et al. Menstrual blood and iron deficiency. Acta Med Scand 1966; 180:639-650.
20. Kane AP, Miller DD. In vitro estimation of the effects of selected proteins on iron bioavailability. Am J Clin Nutr 1984; 39:393-401.
21. Eldor A, Manny N, Izak G. The effect of transferrin-free serum on the utilization of iron by rabbit reticulocytes. Blood 1970; 36(2):233-238.
22. Roy CN, Enns CA. Iron homeostasis: new tales from the crypt. Blood 2000; 6:181-186.
23. Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, Loreal O. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 2001; 276(11):7811-7819.
24. Krause A, Neitz S, Magert HJ, Schulz A, Forssmann WG, Schulz-Knappe P, Adermann K. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett 2000; 480(2-3):147-150.
25. Fleming RE, Sly WS. Hepcidin: a putative iron-regulatory hormone relevant to hereditary hemochromatosis and the anemia of chronic disease. Proc Natl Acad Sci USA 2001; 98(15):8160-8162. Review.
26. Weinstein DA, Roy CN, Fleming MD, Loda MF, Wolfsdorf JI, Andrews NC. Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. Blood 2002; 100(10):3776-3781.
27. Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, Beaumont C, Kahn A, Vaulont S. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002; 110(7):1037-1044.
28. Frazer DM, Wilkins SJ, Becker EM, et al. Hepcidin expression inversely correlates with the expression of duodenal iron transporters and iron absorption in rats. Gastroenterology 2002; 123:835-844.
29. Yamaji S, Sharp P, Ramesh B, Srai SK. Inhibition of iron transport across human intestinal epithelial cells by hepcidin. Blood June 3, 2004 [Epub ahead of print].
30. Taes YE, Wuyts B, Boelaert JR, De Vriese AS, Delanghe JR. Prohepcidin accumulates in renal insufficiency. Clin Chem Lab Med 2004; 42(4):387-389.
31. Bainton DF, Finch CA. The diagnosis of iron deficiency anemia. Am J Med 1964; 37:62-70.
32. Fernandez-Rodriguez AM, Guindeo-Casasus MC, Molero-Labarta T, et al. Diagnosis of iron deficiency in chronic renal failure. Am J Kidney Dis 1999; 34:508-513.
33. Fishbane S, Kowalski EA, Imbriano LJ, Maesaka JK. The evaluation of iron status in hemodialysis patients. J Am Soc Nephrol 1996; 7:2654-2657.
34. Kalantar-Zadeh K, Hoffken B, Wunsch H, et al. Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era. Am J Kidney Dis 1995; 26:292-299.
35. Cazolla M, Ascari E. Red cell ferritin as a diagnostic tool. Br J Haematol 1986; 62:209-213.
36. Schaefer RM, Schaefer L. The hypochromic red cell: a new parameter for monitoring iron supplementation during rhEPO therapy. J Perinat Med 1995; 23:83-88.
37. Eschbach JW, Cook JD, Finch CA. Iron absorption in chronic renal disease. Clin Sci 1970; 38:191-196.
38. Gokal R, Millard PR, Weatherall DJ, et al. Iron metabolism in hemodialysis patients: a study of the management of iron therapy and overload. Q J Med 1979; 191:369-391.
39. Goch J, Birgegard G, Danielson BG, Wikstrom B. Iron absorption in the patient with chronic uremia on maintenance hemodialysis and in healthy volunteers measured with a simple oral iron load test. Nephron 1996; 73:403-406.
40. Spivak JL. Iron and anemia of chronic disease. Oncology (Huntington) 2002; 16(9 Suppl 10):25-33.
41. Means RT, Krantz SB. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 1992; 80:1639-1647.
42. Wingard RL, Parker RA, Ismail N, Hakim RM. Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. Am J Kidney Dis 1995; 25:433-439.
43. Markowitz GS, Kahn GA, Feingold RE, et al. An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin. Clin Nephrol 1997; 48:34-40.
44. Silverberg DS, Iaina A, Peer G, Kaplan E, Levi BA, Frank N, Steinbruch S, Blum M. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis. Am J Kidney Dis 1996; 27(2):234-238.
45. Akmal M, Sawelson S, Karubian F, Gadallah M. The prevalence and significance of occult blood loss in patients with predialysis advanced chronic renal failure (CRF), or receiving dialytic therapy. Clin Nephrol 1994; 42(3):198-202.
46. Fam AG, Howey S, Taylor JJ, Hocker AG. Iron absorption in chronic renal failure. Proc Eur Dial Transplant Assoc 1970; 7:81-85.
47. Boddy K, Lawson DH, Linton AL, Will G. Iron metabolism in patients with chronic renal failure. Clin Sci 1970; 39:115-121.
48. Anagoston A, Kurtzman NA. The anemia of chronic renal failure. Semin Nephrol 1985; 5:115-127.
49. Eschbach J, Egrie J, Downing M, Browne JK, Adamson JW. Correction of anemia of end-stage renal disease with recombinant human erythropoietin. N Engl J Med 1987; 316:73-78.
50. Eschbach JW, Adamson JW. Disorders of RBC production in uremia. Arch Int Med 1970; 126(5):812-815.
51. Hudson JQ, Comstock TJ. Considerations for optimal iron use for anemia due to chronic kidney disease. Clin Ther 2001; 23(10):1637-1671.
52. Hamstra RD, Block MH, Schocket AL. Intravenous iron dextran in clinical medicine. JAMA 1980; 243(17):1726-1731.
53. Nissenson AR, Lindsay RM, Seligman SS. Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American clinical trial. Am J Kidney Dis 1999; 33(3):471-482.
54. Panesar A, Agarwal R. Safety and efficacy of sodium ferric gluconate complex in patients with chronic kidney disease. Am J Kidney Dis 2002; 40(5):924-931.
55. Charytan C, Levin N, Al-Saloum M, Hafeez T, Gagnon S, Van Wyck DB. Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American clinical trial. Am J Kidney Dis 2001; 37(2):300-307.
56. Blaustein DA, Schwenk MH, Chattopadhyay J, Singh H, Daoui R, Gadh R, Avram MM. The safety and efficacy of an accelerated iron sucrose dosing regimen in patients with chronic kidney disease. Kidney Int 2003; (87 Suppl):S72-S77.
57. Hamstra RD, Block MH, Schocket A. Intravenous iron dextran in clinical medicine. JAMA 1980; 243:1726-1731.
58. Stivelman JC. Optimization of iron therapy in hemodialysis patients treated with rHuEPO. Semin Dial 1994; 7:288.
59. Patruta SI, Edlinger R, Sunder-Plassmann G, Horl WH. Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency. J Am Soc Nephrol 1998; 9:655-663.
60. Seligman P, Schleicher R, Meyer G, et al. Fast IV iron: sodium ferric gluconate complex (SFGC) is safe with no "free" iron toxicity [Abstract]. J Am Soc Nephrol 2000; 11:278A.
61. Kimko HC, Kanthu D, Nissenson A, Strobos J, Seligman P. Evidence for iron delivery to erythroid marrow by sodium ferric gluconate complex [Abstract]. J Am Soc Nephrol 2000; 11:297A-298A.
62. Zager RA, Johnson AC, Hanson SY, Wasse H. Parenteral iron formulations: a comparative toxicology analysis and mechanisms of cell injury. Am J Kidney Dis 2002; 40(1):90-103.
63. Zager RA, Johnson AC, Hanson SY. Parenteral iron nephrotoxicity: potential mechanisms and consequences. Kidney Int 2004; 66(1):144-156.
64. Kovistra MP, Kerstry S, Gosriwatanna I, et al. Non transferrin-bound iron in the plasma of haemodialysis patients after intravenous iron saccharate infusion. Eur J Clin Invest 2002; 32(Suppl I):S36-S41.
65. Rooyankken TM, Stroes ECG, Kooistra MP, et al. Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. Eur J Clin Invest 2002; 32(Suppl I):S9-S19.
66. Milman N, Larsen L. Iron absorption in patients with chronic renal failure not requiring dialytic therapy. Acta Med Scand 1975; 198(6):511-517.
67. Milman N, Christensen TE, Pedersen NS, Visfeldt J. Serum ferritin and bone marrow iron in non-dialysis, peritoneal dialysis and hemodialysis patients with chronic renal failure. Acta Med Scand 1980; 207(3):201-205.
68. Fudin R, Jaichenko J, Shostak A, Bennett M, Gotloib L. Correction of uremic iron deficiency anemia in hemodialyzed patients: a prospective study. Nephron 1998; 79(3):299-305.
69. Silverberg DS, Blum M, Agbaria Z, Deutsch V, Irony M, Schwartz D, Baruch R, Yachnin T, Steinbruch S, Iaina A. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period. Clin Nephrol 2001; 55(3):212-219.
70. Silverberg DS, Blum M, Agbaria Z, Schwartz D, Zubkov A, Yachnin T, Iaina A. Intravenous iron for the treatment of predialysis anemia. Kidney Int 1999; 69(Suppl):S79-S85.
71. Trivedi HS, Brooks BJ. Erythropoietin therapy in pre-dialysis patients with chronic renal failure: lack of need for parenteral iron. Am J Nephrol 2003; 23(2):78-85.
72. Levin A. How should anaemia be managed in pre-dialysis patients? Nephrol Dial Transplant 1999; 14(Suppl 2):66-74.
73. Prasad V, Bhullar JK, Schwartz AB. Latent iron deficiency revealed in patients with chronic kidney disease during recombinant human erythropoietin therapy may require treatment with parenteral iron [Abstract]. Am J Kidney Dis 2004; 43(4):B15.92.